Pharmacogenomic Data Might Suffice For Retrospective Analysis, FDA's Temple Says
This article was originally published in The Pink Sheet Daily
Phase III trials could be examined in a two-step process, Office of Medical Policy Director Temple says during workshop on pharmacogenomics in drug development. The data from the second half a trial could test a hypothesis generated from examining the first half if the data are "very persuasive."
You may also be interested in...
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts